EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
复制标题
DOI：
10.1100/tsw.2008.117
复制
发表时间：
2008-09-21
影响因子：
--
通讯作者：
Salgia R
中科院分区：
文献类型：
--
作者：
Sattler M;Abidoye O;Salgia R
头颈部和肺癌与高发病率和死亡率有关，尽管在同一时期放射治疗和化疗取得了进展，但30多年来这些发病率和死亡率相对保持不变。人们普遍认为，标准治疗方案对这些癌症的疗效已经达到了平台期。实体瘤中特定异常分子信号通路的发现为新的靶向癌症治疗提供了有希望的新方向。其中，表皮生长因子受体(EGFR)有望成为治疗靶点。临床研究表明，这种有针对性的方法提供了临床上有意义的好处。本文综述了EGFR靶向治疗的使用和开发，重点介绍了EGFR在头颈部和肺癌的病理生理学中的作用，以及正在研究的新概念，以改善这些药物的疗效。
Cancers of the head and neck and of the lung are associated with high morbidity and mortality rates that have remained relatively unchanged for more than 3 decades, despite advances in radiation therapies and chemotherapies over the same time. It is generally believed that the efficacy of standard therapy regimens has reached a plateau for these cancers. The discovery of specific aberrant molecular signaling pathways in solid tumors has afforded promising new directions for newer “targeted” cancer therapeutics. Among these, the epidermal growth factor receptor (EGFR) shows promise as a therapeutic target. Clinical studies have demonstrated that this targeted approach provides clinically meaningful benefit. This article reviews EGFR-targeted therapies in use and in development, with a focus on the role of EGFR in the pathophysiology of head and neck and lung cancer, and new concepts being investigated to improve outcomes with these agents.
登录
查看更多内容
影响因子：
158.5
作者：
Bonner, JA;Harari, PM;Ang, KK
通讯作者：
Ang, KK
影响因子：
45.3
作者：
Curran, Desmond;Giralt, Jordi;Bonner, James A.
通讯作者：
Bonner, James A.
影响因子：
45.3
作者：
Hirsch, FR;Varella-Garcia, M;Gandara, DR
通讯作者：
Gandara, DR
影响因子：
45.3
作者：
Hotta, K;Matsuo, K;Tanimoto, M
通讯作者：
Tanimoto, M
影响因子：
45.3
作者：
Hanna, Nasser;Lilenbaum, Rogerio;Bonomi, Philip
通讯作者：
Bonomi, Philip